AR007479A1 - Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende. - Google Patents

Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.

Info

Publication number
AR007479A1
AR007479A1 ARP970102792A ARP970102792A AR007479A1 AR 007479 A1 AR007479 A1 AR 007479A1 AR P970102792 A ARP970102792 A AR P970102792A AR P970102792 A ARP970102792 A AR P970102792A AR 007479 A1 AR007479 A1 AR 007479A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituted
hydroxy
hydrogen
alkyl
Prior art date
Application number
ARP970102792A
Other languages
English (en)
Original Assignee
Angelo Noel D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angelo Noel D filed Critical Angelo Noel D
Publication of AR007479A1 publication Critical patent/AR007479A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen derivados de ácido N,N-di(2-hidroxibencil)etilendiamina-N,N- di-acético de la fórmula (I). Se refiere al uso de compuestos derivados del3,5-difenil-1,2,4-triazol sustituido de fórmula (II), donde R1 y R3, en forma simultánea oindepend iente la una de la otra, son hidrógeno, halógeno,hidroxilo, alquilo inferior, halo-alquilo inferior, alcoxi inferior, halo-alcoxi inferior, carboxilo, carbamaoilo, N-alquilcarbamoilo inferior,N,N-dialquilcarbamoilo inferior onitrilo; R2 y R4, en forma simultánea o independiente la una de la otra, son hidrógeno, alcanoilo o aroilo inferior nosustituido, o un radical que se puede extraer bajo condiciones fisiológicas; R3 es hidrógeno, alquilo inferior, hidroxi-alquilo inferior , halo-alquiloinferior, carboxi-alquilo inferior, alcoxicarbonilo inferior-alquilo inferior; R6R7N-C(O)-alquilo inferior, arilo o aril-alquilo inferior nosustituido o sustituido, o heteroarilo o heteroaralquilo nosustituido o susti tuido; R6 y R7, en forma simultánea o independiente la una de la otra, sonhidrógeno, alquilo inferior hidroxi-alquilo inferior, alcoxi-alquilo inferior hidroxialcoxi-alquilo inferior, amino-alquilo inferior N-alquilaminoinferior-alquilo, N,N-di-al quilamino inferior-alquilo inferior, N-(hidroxi-alquilo inferior)amino-alquilo inferior, N,N-di-(hidroxi-alquilo inferior)amino-alquiloinferior o, junto con el átomo de nitrógeno al cual se encuentran unidos, formanuna cadena cerrada aza alicíclica; y las sales de los mismos; en eltratamiento de enfermedades que provocan un exceso de metal en el cuerpo humano o animal o bien son provocadas por él y a ciertos de estos compuestoscomo tales o sus sales, aun procedimiento para pr epararlos y a una composición farmacéutica que los comprende.
ARP970102792A 1996-06-25 1997-06-25 Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende. AR007479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25

Publications (1)

Publication Number Publication Date
AR007479A1 true AR007479A1 (es) 1999-10-27

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102792A AR007479A1 (es) 1996-06-25 1997-06-25 Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.

Country Status (37)

Country Link
US (3) US6465504B1 (es)
EP (1) EP0914118B1 (es)
JP (1) JP3541042B2 (es)
KR (1) KR100616378B1 (es)
CN (1) CN1146415C (es)
AP (1) AP1127A (es)
AR (1) AR007479A1 (es)
AT (1) ATE226435T1 (es)
AU (1) AU718037B2 (es)
BG (1) BG64248B1 (es)
BR (1) BR9709973A (es)
CA (1) CA2255951C (es)
CY (2) CY2429B1 (es)
CZ (1) CZ291470B6 (es)
DE (3) DE122007000020I2 (es)
DK (1) DK0914118T3 (es)
ES (1) ES2187785T3 (es)
FR (1) FR06C0049I2 (es)
GE (1) GEP20084355B (es)
HK (1) HK1020530A1 (es)
HU (1) HU226232B1 (es)
IL (1) IL127212A0 (es)
LT (1) LTC0914118I2 (es)
LU (1) LU91291I2 (es)
MY (1) MY129541A (es)
NL (1) NL300248I2 (es)
NO (3) NO317180B1 (es)
NZ (1) NZ333308A (es)
OA (1) OA10946A (es)
PL (1) PL194758B1 (es)
PT (1) PT914118E (es)
RU (1) RU2208010C2 (es)
SI (1) SI0914118T1 (es)
SK (1) SK284319B6 (es)
TR (1) TR199802693T2 (es)
TW (1) TW533205B (es)
WO (1) WO1997049395A1 (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
JP2007514699A (ja) * 2003-12-19 2007-06-07 ノバルティス アクチエンゲゼルシャフト （ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2594687C (en) * 2005-01-28 2013-10-29 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition
CA2608709A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
JP2009512652A (ja) * 2005-10-19 2009-03-26 ノバルティス アクチエンゲゼルシャフト 安息香酸誘導体含有分散錠
EP1945272B1 (en) 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
WO2008005624A2 (en) 2006-05-23 2008-01-10 Novartis Ag Method of treatment of hereditary hemochromatosis
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
KR20090035737A (ko) * 2006-08-04 2009-04-10 노파르티스 아게 철 킬레이터를 이용한 내분비 기능장애의 치료
JP2010511012A (ja) * 2006-11-29 2010-04-08 ノバルティス アーゲー デフェラシロックス（ｉｃｌ６７０ａ）の多形形態
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
CA2685043A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
WO2010107500A1 (en) 2009-03-19 2010-09-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
EP2509423B1 (en) * 2009-12-07 2016-01-27 Mapi Pharma Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
ES2543427T3 (es) 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
US8907083B2 (en) 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
EP2664333B1 (en) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
RU2659034C2 (ru) * 2013-03-06 2018-06-27 Биокон Лимитед Способ получения деферазирокса
NZ711179A (en) * 2013-03-08 2018-07-27 Novartis Ag Oral formulations of deferasirox
AU2014264421A1 (en) * 2013-05-10 2015-12-03 Cipla Limited Low dose pharmaceutical composition
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CR20160425A (es) 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
TR201909052T4 (tr) 2014-05-20 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroks içeren suda dağılabilen tablet formülasyonu.
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
MY190404A (en) 2015-03-10 2022-04-21 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
NZ740675A (en) 2015-10-23 2024-02-23 Vifor Int Ag Novel ferroportin inhibitors
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
US20190091204A1 (en) 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (es) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
OA10946A (en) 2003-02-27
NO986024D0 (no) 1998-12-21
TW533205B (en) 2003-05-21
LU91291I9 (es) 2018-12-27
CY2007005I1 (el) 2010-07-28
MY129541A (en) 2007-04-30
NL300248I2 (nl) 2007-03-01
DE69716602D1 (de) 2002-11-28
ES2187785T3 (es) 2003-06-16
CA2255951C (en) 2006-10-10
CN1146415C (zh) 2004-04-21
EP0914118A1 (en) 1999-05-12
JP2000507601A (ja) 2000-06-20
SI0914118T1 (en) 2003-04-30
NO2018014I1 (no) 2018-04-17
DE69716602T2 (de) 2003-06-26
US6723742B2 (en) 2004-04-20
NZ333308A (en) 2000-05-26
FR06C0049I1 (es) 2007-03-09
HK1020530A1 (en) 2000-05-12
DK0914118T3 (da) 2003-02-24
NL300248I1 (nl) 2007-02-01
CA2255951A1 (en) 1997-12-31
CY2007005I2 (el) 2018-12-12
KR100616378B1 (ko) 2006-08-28
RU2208010C2 (ru) 2003-07-10
NO2006017I2 (no) 2011-07-04
WO1997049395A1 (en) 1997-12-31
CZ427298A3 (cs) 1999-03-17
PT914118E (pt) 2003-02-28
JP3541042B2 (ja) 2004-07-07
US6596750B2 (en) 2003-07-22
US20030069273A1 (en) 2003-04-10
GEP20084355B (es) 2008-04-29
NO986024L (no) 1998-12-21
TR199802693T2 (xx) 1999-05-21
CN1223579A (zh) 1999-07-21
HU226232B1 (en) 2008-07-28
AP1127A (en) 2002-12-06
LTPA2007001I1 (lt) 2018-06-25
US20030203954A1 (en) 2003-10-30
AU3262997A (en) 1998-01-14
CY2429B1 (en) 2004-11-12
LTC0914118I2 (lt) 2018-12-27
BG64248B1 (bg) 2004-07-30
CZ291470B6 (cs) 2003-03-12
KR20050098029A (ko) 2005-10-10
PL194758B1 (pl) 2007-07-31
NO2006017I1 (no) 2006-12-18
IL127212A0 (en) 1999-09-22
ATE226435T1 (de) 2002-11-15
HUP9903111A3 (en) 2000-06-28
FR06C0049I2 (fr) 2007-04-27
HUP9903111A2 (hu) 2000-01-28
LU91291I2 (fr) 2007-01-29
AU718037B2 (en) 2000-04-06
PL330119A1 (en) 1999-04-26
BG103003A (en) 1999-09-30
EP0914118B1 (en) 2002-10-23
SK178598A3 (en) 1999-06-11
DE122007000020I1 (de) 2007-05-24
DE122007000020I2 (de) 2010-12-30
US6465504B1 (en) 2002-10-15
NO2018014I2 (no) 2018-11-19
BR9709973A (pt) 1999-08-10
NO317180B1 (no) 2004-09-06
AP9801407A0 (en) 1998-12-31
SK284319B6 (sk) 2005-01-03

Similar Documents

Publication Publication Date Title
AR007479A1 (es) Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.
RU2003135482A (ru) Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения
EA200100742A1 (ru) Применение 4-h-1-бензопиран-4-оновых производных в качестве ингибиторов пролиферации клеток гладких мышц
RU2003130058A (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69939705D1 (de) Behandlung der pompeschen krankheit
NZ243443A (en) Triazolopyrimidine derivatives, preparation and pharmaceutical compositions thereof
TR200101633T2 (tr) Farmasötik bileşim
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
SE9903611D0 (sv) Novel compounds III
ES8201955A1 (es) Un procedimiento de produccion de derivados del acido 2-hi- droxioxanilico
RU2003104017A (ru) Ингибиторы тромбина, содержащие аминоизохинолиновую группу
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
IE790157L (en) Therapeutic agents
KR920019767A (ko) 티아졸 유도체
RU98114091A (ru) Вещества, связывающие рецепторы гиалуроновой кислоты и их применение
RU99116652A (ru) Способ лечения злокачественной лимфомы кожи
KR880006236A (ko) 이소퀴놀린 유도체
FR2224152A1 (en) Thiazolotriazolyl phosphorothioates as anthelmintics - combining good anthelmintic activity with low toxicity to warm-blooded animals
EP0717980A2 (en) Use of guanidine-imidazole derivatives to assist hair growth stimulation
RU2002129102A (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
RU95116239A (ru) Применение 5-тиа-1,4-диазабицикло[4.2.0]октан-3,8-диоксопроизводных в противоопухолевой терапии
TH49153B (th) ยานำ (prodrug) ของสารยับยั้งแอสพาร์ทิลโปรทีเอส

Legal Events

Date Code Title Description
FG Grant, registration